Consistently, a correlation of SEC62 amplification with overall survival in 40,006 cancer patients (45 different tumor entities) based on publicly available DNA sequencing and clinical data (cBio Portal for cancer genomics; https://www.cbioportal.org, accessed on 21 April 2021) shows a highly significant association of SEC62 amplifications with poor prognosis (Figure 10b). This evidence concerns the gene SEC62 and neoplasm.